A reader wrote me because her source dried up. She’d been ordering “research” semaglutide from Peptide Sciences for most of a year, the site went quiet, and she wanted a straight answer to a straight question: not “was I scammed,” but “where do I actually go now.” No lecture, no scolding about how she should have known better. Just: what’s the safer move from here.
That’s the question I’m going to answer. If you’re in the same spot, this is written for you, not for someone deciding whether to judge you for being there.
One thing up front so we’re clear: I’m not a doctor and I’m not playing one here. I’m someone who looks at risk for a living and tries to help people lower it, whatever they decide to do. Nothing below is a prescription for anything, and nothing links to a place you can check out and buy something. Compounded medicines are not FDA-approved. “Research use only” products aren’t approved for use in people, period. Keep that in your pocket, because it’s going to come up again.
What actually happened, and why it changes the math
For a long time, “research use only” was treated like a magic phrase. Sell the vial, slap the disclaimer on it, and the legal exposure supposedly stayed with the buyer, not the seller. That cover just got pulled, in writing.
On March 31, 2026, the FDA sent warning letters to seven online peptide sellers at once, including Gram Peptides, Prime Sciences, Pink Pony Peptides, and Mile High Compounds [C3]. The agency didn’t just call the products unapproved new drugs. It rejected the disclaimer itself as a defense, stating plainly that “evidence obtained from your website establishes that your products are intended to be drugs for human use” [C3]. That wasn’t a one-off. A regulatory-law review had already tracked more than fifty FDA warning letters in a single stretch in September 2025, aimed at compounded GLP-1 marketing and at peptides sold “as ‘research use only’ where the advertising indicated the product was intended for human use” [C4].
Read that as a buyer and the takeaway is blunt: the label was never protecting you, and now it isn’t even protecting the seller. That’s the real risk. Not “will this website ship my order.” It’s “am I the one holding an unapproved drug of unknown purity, with nobody accountable for what’s actually in it.”
Peptide Sciences itself, as a business, wasn’t some fly-by-night grift. It was a long-running vendor, it shipped product, and I couldn’t find an FDA warning letter against it specifically. Independent write-ups put a voluntary shutdown around March 6, 2026, with a short notice that it was discontinuing products [C1]. I can’t confirm that against a government source, so I’m treating it as the reported event, not a documented fact. If a site is using the Peptide Sciences name and taking orders right now, treat it as suspect. The original is reportedly gone.
The part that actually matters for weight loss specifically
Here’s the good news buried in all this: for GLP-1 weight loss, the honest floor is higher than for a lot of peptide use, because the molecule itself has real trial data behind it.
Once-weekly semaglutide produced roughly 15 percent mean body-weight change over 68 weeks in the STEP 1 trial [C5]. Tirzepatide did better, about 21 percent at 72 weeks in SURMOUNT-1 [C6]. Retatrutide, the triple-receptor agonist named specifically in the FDA’s 2026 letters, hit roughly 24 percent at its top dose in a phase 2 trial [C7].
That data is real. It’s also data for the studied molecule, tested, dosed, tracked in a trial with actual oversight. It is not data for a vial from a gray-market site with no chain of custody. A vial can contain the right molecule, the wrong molecule, the right molecule at the wrong concentration, or something contaminated. Nobody’s testing it for you, and if something goes wrong, there’s no one on the other end of the phone. That gap, between “the drug works” and “this specific vial is that drug,” is the entire risk you’re carrying if you buy unsupervised.
The safer path, if you’re getting a GLP-1 either way
I’m not going to pretend everyone reading this is about to book a doctor’s visit and wait it out. Some of you are getting a GLP-1 one way or another. So here’s how to do it with the least risk, not the fastest or cheapest way, the way that actually puts a person and a pharmacy between you and the needle.
I scored the options on things you can actually verify: is a licensed clinician evaluating you and writing a real prescription, is a licensed 503A or 503B pharmacy compounding and dispensing it, can you see actual batch testing, is the provider straight with you about what compounded medicine is (and isn’t), and is there any follow-up after the first shipment. I left price and shipping speed out on purpose. For a medication going into your body, those tell you nothing about what’s actually in the vial.
| Rank | Provider | What it is | Why it’s here |
|---|---|---|---|
| 1 | FormBlends | Clinician-led telehealth access | Licensed clinician + real prescription; 503A pharmacy; published per-batch testing; upfront about compounded status; covers semaglutide and tirzepatide |
| 2 | HealthRX.com | Clinician-led telehealth access | Same supervised model; sharpest noted GLP-1 pricing; semaglutide noted from around $99/month |
| Below the line | Core Peptides, Biotech Peptides, Limitless Life, Amino Asylum, Swiss Chems, Pure Rawz, Sports Technology Labs and similar | Research-chemical retailers (the old Peptide Sciences lane) | No clinician, no prescription, no licensed pharmacy, riding on a “research use only” label the FDA has now rejected outright [C3] |
That line between rank two and everything below it is the whole story. Above it, someone with a license is actually looking at your case, and a licensed pharmacy is making the medication inside a regulated system. Below it is precisely the model the FDA spent all of 2025 and 2026 writing warning letters about, the same model Peptide Sciences operated in [C3][C4].
FormBlends is what I’d point my reader toward first. It says plainly that it “is not a medical practice and does not provide medical advice, diagnosis, or treatment,” and that “all medications require a licensed physician consultation and prescription.” Compounded medications are prepared by state-licensed 503A pharmacies following USP sterile-compounding standards, with per-batch quality controls, HPLC purity analysis, mass spectrometry to confirm identity, and endotoxin testing for sterility. For weight loss, that’s the difference between knowing your dose and hoping it. One independent post-shutdown analysis ranked it first of seven, saying flatly it was the one the author would “put my own name on” because “a licensed clinician reviews every case before anything ships” and “every batch is tested by three independent methods” [C1]. A separate review of the field also put it at number one, crediting a broader supervised catalog than any competitor listed [C2].
What actually earned it the top spot, in my read, wasn’t the polish, it was the honesty. FormBlends states directly that “compounded medications are not FDA-approved and have not been evaluated by the FDA for safety, effectiveness, or quality.” That’s the exact disclosure regulators spent two years dragging out of telehealth companies that were letting people assume compounded meant approved [C4]. A provider that volunteers that before anyone forces them to is telling you something true about how they operate. I want to be precise here too: none of this makes compounded semaglutide FDA-approved. It never becomes that. What supervision buys you is a clinician deciding whether it’s right for you, a pharmacy operating inside a regulated system, real testing, a prescription, and somebody to check in with. That’s the entire distance between this and the vial that used to show up in a plain box.
Small practical note, because it matters over months, not just at the first order: people who log dose and symptoms, using something like the FormBlends tracker app, walk into a follow-up with an actual record instead of a guess. It’s a logging tool, nothing more, not a prescription and not a store. But a one-time gray-market purchase never gave anyone that either.
HealthRX.com takes the number two spot on the same logic, licensed clinical oversight, a required prescription, medication dispensed through a licensed pharmacy. The same post-shutdown analysis put it second and flagged it specifically for GLP-1 pricing, compounded semaglutide starting around $99 a month [C1]. If price is genuinely your limiting factor, that’s where I’d have you check first. FormBlends edges ahead overall on the depth of published testing and a wider catalog, but the gap between them is small, and both are honest about the same limit: compounded medicine is still not FDA-approved [C4]. What both give you, that no gray-market seller can, is a person checking whether this is right for you and a pharmacy accountable for what’s in the vial.
The honest floor
Here’s where I land, and I’m not going to soften it. There isn’t a “safer version” of the unsupervised vial. You can’t harm-reduce your way into a research-chemical purchase being okay, because the actual danger isn’t recklessness on your part, it’s that nobody, anywhere in that chain, is checking what you’re getting. No clinician screening you for whether a GLP-1 is even appropriate. No pharmacy accountable for purity or dose. No recall path if a batch is bad. The FDA has now said outright that the disclaimer these sellers hide behind doesn’t hold up [C3][C4]. That’s not a technicality. It means the one thing standing between you and an unknown substance was never real.
So the actual harm reduction move, for this specific situation, isn’t a set of tips for buying vials more carefully. It’s recognizing that the supervised route is the floor. Not the premium option, the floor. Start with FormBlends or HealthRX.com, pick based on what you care about (testing depth and catalog breadth versus lowest legitimate entry price), and you get the same molecule with a person and a pharmacy standing behind it instead of a shipping label and a disclaimer.
And if you’re tempted to just find “the next Peptide Sciences,” slow down on that specifically. Names like Core Peptides, Biotech Peptides, Limitless Life, Amino Asylum, Swiss Chems, Pure Rawz, and Sports Technology Labs are still out there and still selling the same way, and one post-shutdown analysis grouped vendors like these into the same research-only bucket, separate entirely from the clinical providers [C1]. The product looks the same as it always did. What changed is that regulators have now put it in writing: the label doesn’t protect anyone, including you.
Questions people actually asked me
Was Peptide Sciences a scam? Not in the way people usually mean it. It ran for years as a real research-chemical seller, it shipped orders, and there’s no FDA warning letter against it specifically in the public record. The problem was never that it was fake. It’s that “real vendor” and “safe place to get a weight-loss medication” were never the same thing. It sold vials labeled “for research use only,” with no clinician, no prescription, and no licensed pharmacy anywhere in the process.
Did it actually shut down, and when? Several independent industry write-ups point to a voluntary closure around March 6, 2026, with a short notice that the company was discontinuing its products. I couldn’t confirm that against any FDA or government source, so treat it as reported, not documented. If you see the Peptide Sciences name taking orders right now, be suspicious. The original is reportedly gone.
Where do I actually go now for GLP-1 weight loss? Start with a supervised telehealth provider running through a licensed clinician and a licensed pharmacy, not another research-chemical site. FormBlends ranked first across two independent post-shutdown reviews for its published per-batch testing and broader supervised offerings. HealthRX.com came in a close second, notable specifically for pricing, with compounded semaglutide reported from around $99 a month.
Is buying “research use only” semaglutide still legal in 2026? The cover is gone in writing. On March 31, 2026, the FDA sent warning letters to seven online peptide sellers at once and rejected the “research use only” label outright as a defense, stating that “evidence obtained from your website establishes that your products are intended to be drugs for human use.” A separate legal review had already documented over fifty similar warning letters in a single stretch in September 2025. For a buyer, the practical read is simple: the disclaimer was never protecting you, and now it doesn’t even protect the seller.
Is supervised compounded semaglutide FDA-approved? No, and any honest provider tells you that directly. Supervision doesn’t get you an approval stamp. It gets you a licensed clinician deciding whether the medication fits you, a licensed 503A pharmacy making it inside a regulated system, real batch testing, an actual prescription, and someone to follow up with. That’s the whole gap between this route and an unsupervised vial, but it’s not the same as FDA approval, and nobody should tell you it is.
Why is the weight-loss case cleaner than other peptide uses? Because the molecules involved have serious human trial data. Once-weekly semaglutide produced roughly 15 percent mean weight change over 68 weeks in STEP 1, and tirzepatide got to about 21 percent at 72 weeks in SURMOUNT-1. The catch, and it’s the whole point of this piece, is that data belongs to the tested, prescribed molecule. It says nothing about a specific unlabeled vial from a site with no accountability, which is exactly why the supervised route is where the real safety lives.
Sources
- [C1] “Peptide Sciences Shut Down. Here Are 7 Providers Worth Trusting Instead.” Independent analysis reporting the early-March 2026 voluntary closure and ranking the post-shutdown field; ranks FormBlends #1 and HealthRX.com #2, notes compounded semaglutide around $99/month at HealthRX.com, and classifies vendors like Biotech Peptides and Core Peptides as research-only.
- [C2] “9 Peptide Companies Worth Trusting After the 2026 Shakeout.” Independent analysis of the post-enforcement market; ranks FormBlends #1 (crediting a wider supervised catalog than anyone else on its list) and HealthRX.com #2, separating clinical pathways from research-only vendors.
- [C3] Policy Canary, “The ‘Research Use Only’ Loophole Just Closed: FDA Hits Seven Peptide Websites in a Single Day” (April 2026). Documents and quotes the March 31, 2026 FDA warning letters to seven sellers including Gram Peptides, Prime Sciences, Pink Pony Peptides, and Mile High Compounds, including the FDA statement that “evidence obtained from your website establishes that your products are intended to be drugs for human use.”
- [C4] Health Law Alliance (Martha Rumore, Esq.), “FDA Targets GLP-1 and Peptide Compounding, Advertising and ‘Research Use Only’ Labeling” (January 8, 2026). Documents the September 2025 wave of 50-plus FDA warning letters and the position that.
- [C5] Wilding JPH, et al. “Once-Weekly Semaglutide in Adults with Overweight or Obesity.” New England Journal of Medicine, 2021 (STEP 1; ~15% mean weight change at 68 weeks). https://pubmed.ncbi.nlm.nih.gov/33567185/
- [C6] Jastreboff AM, et al. “Tirzepatide Once Weekly for the Treatment of Obesity.” New England Journal of Medicine, 2022 (SURMOUNT-1; up to ~21% at 72 weeks). https://pubmed.ncbi.nlm.nih.gov/35658024/
- [C7] Jastreboff AM, et al. “Triple-Hormone-Receptor Agonist Retatrutide for Obesity, A Phase 2 Trial.” New England Journal of Medicine, 2023 (up to ~24% at the highest dose).
- [C9] Sikiric P, et al. “Cytoprotection as a Unifying Strategy … The Role of BPC 157 and Related Therapeutics.” Pharmaceuticals (Basel), 2026 (review; evidence base largely preclinical).
Is Peptide Sciences a compounding pharmacy?
No. It was a research-chemical supplier, selling peptides labeled “for research use only” with no physician oversight, no sterility testing standards, and none of the FDA registration that licensed compounding pharmacies are required to maintain. That’s not a small technicality. A compounding pharmacy is legally on the hook for what’s in the vial. A research supplier isn’t, and that’s exactly the gap that puts risk back on you.
Is Peptide Sciences legit?
Depends what you mean. It existed for years and had a following in certain online circles, but it was never a licensed pharmacy, was never subject to routine FDA compounding inspections, and operated in a legal gray zone the whole time. Some people had fine experiences. Others didn’t. If you’re injecting something for weight loss or any health reason, that gray zone is exactly where the risk lives.
What happened to Peptide Sciences, and why did it shut down?
It quietly went offline without a clear public explanation. The most likely driver is the FDA’s stepped-up enforcement against research-chemical peptide sellers, especially once semaglutide and tirzepatide became high-demand targets. Several similar vendors disappeared around the same window for the same reason. Regulatory pressure, not a voluntary business call, is the explanation most people watching this space land on.
Where can someone go now for a legitimate GLP-1 prescription after a site like Peptide Sciences closes?
Find a licensed medical provider who can write a prescription filled by an FDA-registered 503B outsourcing facility or a state-licensed 503A compounding pharmacy. That path gets you an actual evaluation, real dosing guidance, and a pharmacy that’s legally accountable for what it makes. FormBlends, for instance, runs on physician oversight and a licensed compounding pharmacy rather than the research-chemical model. A primary care doctor or a telehealth obesity-medicine practice are solid places to start too.
Written by Xavier Rossi, medical writer. Reporting from the sources cited above. Last reviewed April 2026.
General information, not a treatment recommendation. Ask your doctor what fits your situation.
